Moharamzadeh K, Brook IM, VanNoort R, Scutt AM, Thornhill MH
These combined effects make GLP-1 medications a powerful option for improving overall health in people with these conditions
In contrast, the variability in interindividual response on body weight loss in patients receiving GLP-1 RAs treatment is significantly greater than the variability in glycemic control response [16]
Specifically, analyzed were the affected brain areas (04), cerebral (NTP-7, Level 3), cerebellar cortex (NTP-7, Level 6), and hippocampus, thalamus, and hypothalamus (NTP-7, Level 3) as follows (score 0 indicates no histopathologic change): score 1: small, patchy, complete, or incomplete infarcts (10% of the area affected)
Full-text paper in English
CXXC motif affects the process of leukemogenesis mediated by ROS